• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

“在他们的心目中,他们总是觉得自己低人一等”:同伴在改变阿片类药物使用障碍治疗保留障碍的污名方面的作用。

"In their mind, they always felt less than": The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention.

机构信息

Department of Psychology, University of Maryland, College Park, College Park, MD, USA.

Department of Psychology, University of Maryland, College Park, College Park, MD, USA.

出版信息

J Subst Abuse Treat. 2022 Jul;138:108721. doi: 10.1016/j.jsat.2022.108721. Epub 2022 Jan 16.

DOI:10.1016/j.jsat.2022.108721
PMID:35067397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9167238/
Abstract

INTRODUCTION

A substantial, national need exists for culturally acceptable, accessible opioid use disorder (OUD) treatment. Medication for opioid use disorder (MOUD) is regarded as effective in treating OUD; however, retention in MOUD programs remains low nationally. One known barrier to MOUD retention is stigma, particularly within ethno-racial minority communities. Peer recovery specialists (PRSs), individuals with shared experience in substance use and recovery, may be particularly well suited to support patients in MOUD treatment, and may have capacity to play a key role in decreasing stigma-related barriers to MOUD retention.

METHODS

This study used qualitative methods to solicit feedback on how patients receiving methadone treatment (MT) experience stigma (i.e., toward substance use [SU] and MT). Study staff also gathered information regarding how a PRS role may reduce stigma and improve retention in care, including barriers and facilitators to the PRS role shifting stigma. Study staff conducted semi-structured qualitative interviews and focus groups (N = 32) with staff and patients receiving MT at an opioid treatment program as well as PRSs in Baltimore.

RESULTS

Participants identified experiences of internalized, as well as enacted and anticipated, MT and SU stigma, and described these as barriers to treatment. Participants also identified opportunities for PRSs to shift stigma-related barriers for patients receiving MT through unique aspects of the PRS role, such as their shared lived experience.

CONCLUSIONS

Reducing stigma surrounding SUD and MT is critical for improving MOUD outcomes, and future research may consider how the PRS role can support this effort.

摘要

简介

在文化上可接受且易于获取的阿片类药物使用障碍(OUD)治疗在全国范围内有很大的需求。药物治疗阿片类药物使用障碍(MOUD)被认为是治疗 OUD 的有效方法;然而,全国范围内 MOUD 项目的保留率仍然很低。众所周知,MOUD 保留率的一个障碍是污名化,特别是在族裔少数群体社区中。同伴康复专家(PRS)是指在药物使用和康复方面有共同经历的个体,他们可能特别适合支持接受 MOUD 治疗的患者,并可能在减少与污名相关的 MOUD 保留障碍方面发挥关键作用。

方法

本研究采用定性方法,征求接受美沙酮治疗(MT)的患者对污名体验(即对药物使用和 MT 的污名)的反馈意见。研究人员还收集了关于 PRS 角色如何减少污名化并改善护理保留率的信息,包括 PRS 角色转变污名化的障碍和促进因素。研究人员在巴尔的摩的一个阿片类药物治疗项目中对接受 MT 的工作人员和患者以及 PRS 进行了半结构化定性访谈和焦点小组(N=32)。

结果

参与者确定了内化的、实施的和预期的 MT 和 SU 污名化的经历,并将这些经历描述为治疗的障碍。参与者还确定了 PRS 通过 PRS 角色的独特方面为接受 MT 的患者转变与污名相关的障碍的机会,例如他们共同的生活经历。

结论

减少 SUD 和 MT 周围的污名化对于改善 MOUD 结果至关重要,未来的研究可能会考虑 PRS 角色如何支持这一努力。

相似文献

1
"In their mind, they always felt less than": The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention.“在他们的心目中,他们总是觉得自己低人一等”:同伴在改变阿片类药物使用障碍治疗保留障碍的污名方面的作用。
J Subst Abuse Treat. 2022 Jul;138:108721. doi: 10.1016/j.jsat.2022.108721. Epub 2022 Jan 16.
2
Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.纽约阿片类药物干预法庭中转介和参与物质使用障碍治疗:实施障碍和促进因素的定性研究。
Subst Abuse Treat Prev Policy. 2024 Jan 29;19(1):12. doi: 10.1186/s13011-024-00593-y.
3
"You rise up and then you start pulling people up with you": Patient experiences with a peer-delivered behavioral activation intervention to support methadone treatment.“你奋起,然后开始拉着别人一起进步”:患者对同伴提供的行为激活干预措施以支持美沙酮治疗的体验。
Int J Drug Policy. 2023 Dec;122:104234. doi: 10.1016/j.drugpo.2023.104234. Epub 2023 Oct 21.
4
Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.VA 初级保健中阿片类药物使用障碍的药物处方和接受情况:退伍军人和提供者的观点。
J Gen Intern Med. 2024 Jul;39(9):1690-1697. doi: 10.1007/s11606-024-08703-z. Epub 2024 Apr 8.
5
"Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.“厌倦了生病和疲惫”:探索在无家可归者中开始使用治疗阿片类药物使用障碍的药物。
J Subst Abuse Treat. 2022 Jul;138:108752. doi: 10.1016/j.jsat.2022.108752. Epub 2022 Feb 23.
6
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.州许可的专业物质使用治疗计划中使用丁丙诺啡的障碍和促进因素:对项目领导层的调查。
J Subst Use Addict Treat. 2024 Jul;162:209351. doi: 10.1016/j.josat.2024.209351. Epub 2024 Mar 17.
7
"You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.“你必须服用这种药物,但服用它却会受到惩罚”:围产期治疗阿片类药物使用障碍时缺乏自主性、选择权以及对药物的恐惧。
J Subst Abuse Treat. 2022 Aug;139:108765. doi: 10.1016/j.jsat.2022.108765. Epub 2022 Mar 18.
8
Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses.12步支持小组中针对阿片类药物使用障碍药物的污名化及参与者的反应。
Subst Abus. 2022;43(1):415-424. doi: 10.1080/08897077.2021.1944957. Epub 2021 Jul 2.
9
A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.一项针对 Veterans Health Administration 中涉及法律问题的退伍军人中阿片类药物使用障碍药物治疗的障碍和促进因素的全国性调查。
Subst Abus. 2022;43(1):556-563. doi: 10.1080/08897077.2021.1975867. Epub 2021 Sep 29.
10
Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.干预污名化与阿片类药物使用障碍治疗:系统综述
Subst Use Misuse. 2021;56(14):2181-2201. doi: 10.1080/10826084.2021.1975749. Epub 2021 Sep 20.

引用本文的文献

1
Co-designing a mobile application to reduce self-stigma for people with opioid use disorder during pregnancy and the postpartum period.共同设计一款移动应用程序,以减少孕期和产后患有阿片类药物使用障碍的人群的自我污名感。
Front Psychiatry. 2025 Sep 1;16:1607652. doi: 10.3389/fpsyt.2025.1607652. eCollection 2025.
2
"HEAL together": a randomized, hybrid type 1 effectiveness-implementation trial protocol of a peer-delivered behavioral activation intervention to improve methadone treatment retention.“共同康复”:一项随机、混合型1有效性-实施性试验方案,关于同伴提供的行为激活干预以提高美沙酮治疗留存率
Front Public Health. 2025 Jul 18;13:1637846. doi: 10.3389/fpubh.2025.1637846. eCollection 2025.
3

本文引用的文献

1
Disparities in Opioid Overdose Death Trends by Race/Ethnicity, 2018-2019, From the HEALing Communities Study.2018 - 2019年按种族/族裔划分的阿片类药物过量死亡趋势差异,来自“健康社区研究”。
Am J Public Health. 2021 Oct;111(10):1851-1854. doi: 10.2105/AJPH.2021.306431. Epub 2021 Sep 9.
2
Opioid overdose crises during the COVID-19 pandemic: implication of health disparities.新冠疫情期间的阿片类药物过量危机:健康差异的影响。
Harm Reduct J. 2021 Aug 16;18(1):89. doi: 10.1186/s12954-021-00534-z.
3
Racial/Ethnic Disparities in Unintentional Fatal and Nonfatal Emergency Medical Services-Attended Opioid Overdoses During the COVID-19 Pandemic in Philadelphia.
The role of micro-, meso-, and macro-level stigma on the uptake of medications for opioid use disorder (MOUD) among women in the criminal legal system.
微观、中观和宏观层面的耻辱感对刑事法律系统中女性使用阿片类药物使用障碍药物(MOUD)的影响。
BMC Womens Health. 2025 Jul 25;25(1):370. doi: 10.1186/s12905-025-03863-4.
4
Racial and Ethnic Factors and Opioid Use Disorder Treatment After an Emergency Department Visit.种族和民族因素与急诊科就诊后的阿片类物质使用障碍治疗
JAMA Netw Open. 2025 Jul 1;8(7):e2520661. doi: 10.1001/jamanetworkopen.2025.20661.
5
Development, Validity, and Acceptability of the Peer Recovery Coach (PRC) Service Checklist for Medication for Opioid Use Disorder (MOUD) Support.阿片类药物使用障碍(MOUD)支持用药同伴康复教练(PRC)服务清单的开发、有效性和可接受性。
Subst Use Misuse. 2025;60(11):1583-1590. doi: 10.1080/10826084.2025.2508741. Epub 2025 May 30.
6
Systematizing peer recovery support services for substance use disorder: a taxonomy for measuring recovery milestones.系统化物质使用障碍的同伴康复支持服务:衡量康复里程碑的分类法。
Front Public Health. 2025 May 12;13:1529078. doi: 10.3389/fpubh.2025.1529078. eCollection 2025.
7
Bridge Over Troubled Waters? Certified Recovery Specialist Support and Community Reentry: A Pilot Study.troubled waters上的桥梁?认证康复专家支持与社区重新融入:一项试点研究
Int J Offender Ther Comp Criminol. 2025 Sep;69(12):1761-1780. doi: 10.1177/0306624X251322824. Epub 2025 Feb 24.
8
Social Network Barriers to Extended-Release Naltrexone Within Rural Appalachia: Perspectives from Justice-Involved Clients and Clinicians.美国阿巴拉契亚农村地区长效纳曲酮的社交网络障碍:涉司法客户和临床医生的观点
Subst Use Misuse. 2025;60(5):758-765. doi: 10.1080/10826084.2024.2447430. Epub 2025 Jan 14.
9
Perceptions of substance use disorder in rural areas: how the brain disease model impacts public stigma.农村地区对物质使用障碍的认知:脑部疾病模型如何影响公众污名化。
BMC Public Health. 2024 Dec 18;24(1):3531. doi: 10.1186/s12889-024-20682-8.
10
Adapting a Behavioral Activation Intervention for Opioid Use Disorder and Methadone Treatment Retention for Peer Delivery in a Low-Resource Setting: A Case Series.在资源匮乏环境中调整行为激活干预措施用于阿片类物质使用障碍及美沙酮治疗维持以实现同伴传递:病例系列
Cogn Behav Pract. 2024 Nov;31(4):437-450. doi: 10.1016/j.cbpra.2023.01.003. Epub 2023 Mar 9.
在费城 COVID-19 大流行期间,非故意致命和非致命紧急医疗服务中阿片类药物过量的种族/民族差异。
JAMA Netw Open. 2021 Jan 4;4(1):e2034878. doi: 10.1001/jamanetworkopen.2020.34878.
4
Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19.解决新冠疫情期间阿片类物质使用障碍药物获取方面的种族和社会经济差异问题。
J Subst Abuse Treat. 2021 Mar;122:108214. doi: 10.1016/j.jsat.2020.108214. Epub 2020 Nov 24.
5
Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 - Georgia, March 2020.《2020 年 3 月佐治亚州因 COVID-19 住院的成年患者的特征和临床结局》。
MMWR Morb Mortal Wkly Rep. 2020 May 8;69(18):545-550. doi: 10.15585/mmwr.mm6918e1.
6
Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.美国各县种族/民族隔离与阿片类药物使用障碍治疗能力的关系。
JAMA Netw Open. 2020 Apr 1;3(4):e203711. doi: 10.1001/jamanetworkopen.2020.3711.
7
Structural Racism and the Opioid Overdose Epidemic: The Need for Antiracist Public Health Practice.结构性种族主义与阿片类药物过量流行:反种族主义公共卫生实践的必要性。
J Public Health Manag Pract. 2020 May/Jun;26(3):201-205. doi: 10.1097/PHH.0000000000001168.
8
Stigma and discrimination related to mental health and substance use issues in primary health care in Toronto, Canada: a qualitative study.加拿大多伦多初级卫生保健中心与心理健康和物质使用问题相关的污名和歧视:一项定性研究。
Int J Qual Stud Health Well-being. 2020 Dec;15(1):1744926. doi: 10.1080/17482631.2020.1744926.
9
Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018.药物和阿片类药物相关过量死亡 - 美国,2017-2018 年。
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297. doi: 10.15585/mmwr.mm6911a4.
10
Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in U.S. healthcare settings.美医疗环境中,美沙酮维持治疗与种族歧视经历之间的交互作用。
PLoS One. 2020 Feb 6;15(2):e0228755. doi: 10.1371/journal.pone.0228755. eCollection 2020.